MedPath
HSA Product

Akynzeo® IV Concentrate for Solution for Infusion 235 mg/0.25 mg/vial

Product approved by Health Sciences Authority (SG)

Basic Information

Akynzeo® IV Concentrate for Solution for Infusion 235 mg/0.25 mg/vial

INFUSION, SOLUTION CONCENTRATE

Regulatory Information

SIN16899P

November 28, 2023

Prescription Only

Therapeutic

INTRAVENOUS

January 24, 2024

June 4, 2025

XA04AA55

Company Information

JUNIPER BIOLOGICS PTE LTD

JUNIPER BIOLOGICS PTE LTD

Active Ingredients

Detailed Information

Contraindications

**4 CONTRAINDICATIONS** Pregnancy

Indication Information

**1 INDICATIONS AND USAGE** AKYNZEO IV is indicated in adults for the: - Prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy, including cisplatin. - Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

© Copyright 2025. All Rights Reserved by MedPath